Graft versus Host Disease Practice Updates

Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.

Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.

A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.

Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.

Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.

Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.

A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.

Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.

Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.

A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.

Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.